Search

Displaying results 2921 - 2930 of 10000 in total
  1. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate. … [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]

  2. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    In April 2018, the U.S. … Fosnetupitant is the pro-drug form of netupitant [FDA label].

  3. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.

    Categories: Drugs Used in Benign Prostatic Hypertrophy
  4. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    On August 8, 2001 the U.S. … It has also been withdrawn from the Canadian market.[A669,L43942]

  5. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    [L63797,L63928] The approval is conditional on a proven reduction of proteinuria in the Origin 3 trial, which is evaluating whether the atacicept slows long-term kidney function decline. … [L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy.

    Synonyms: TACI-IG
  6. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    These resistance-associated amino acid substitutions included Q30D/deletion, Y93D/H/N or H58D +Y93H in genotype 1a replicons, F28S + M31I or P29S + K30G in genotype 2a replicons, and Y93H in genotype 3a … Individual NS5A amino acid substitutions that reduced susceptibility to pibrentasvir include M28G or Q30D in a genotype 1a replicon and P32-deletion in a genotype 1b replicon [L940].

  7. Drug

    Levorphanol

    go.drugbank.com/drugs/DB00854
    Approved

    It is nearly as effective orally as by injection.

  8. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  9. Drug

    Carbimazole

    go.drugbank.com/drugs/DB00389
    Approved

    An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.

  10. Drug

    Influenza A virus A/Texas/50/2012 X-223 (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14392
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: AGRIPPAL 2.5 ML IM/SC ENJ.ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR